Recurrent, locally advanced Merkel Cell Carcinoma
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB09037 | Pembrolizumab | A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. |
| DB15766 | Retifanlimab | A PD-1–blocking antibody indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB09037 | Pembrolizumab | Programmed cell death protein 1 | target |
| DB09037 | Pembrolizumab | Programmed cell death 1 ligand 1 | target |
| DB15766 | Retifanlimab | Programmed cell death protein 1 | target |
| Drug | Drug Name | Phase | Status | Count |
|---|